| VG161 / ViroGin Biotech |
NCT06746480: Clinical Study of VG161 in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 33 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Advanced Intrahepatic Cholangiocarcinoma | 09/25 | 12/25 | | |
NCT06126510: Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 40 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Sarcoma | 07/25 | 01/26 | | |
NCT05223816: An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 97 | US | VG161, Nivolumab Injection [Opdivo] | Virogin Biotech Canada Ltd | Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma | 10/25 | 12/25 | | |
NCT05162118: Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 51 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with Nivolumab, VG161 + Nivolumab | Zhejiang University | Advanced Pancreatic Cancer | 03/25 | 12/25 | | |
NCT06008925: Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 1/2 | 43 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161, Nivolumab Injection, OPDIVO | CNBG-Virogin Biotech (Shanghai) Ltd. | Metastatic Gastric Cancer | 12/25 | 06/26 | | |
NCT06124001: Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 1/2 | 36 | NA | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161, camrelizumab for Injection, camrelizumab | CNBG-Virogin Biotech (Shanghai) Ltd. | Primary Hepatocellular Carcinoma | 12/25 | 06/26 | | |
NCT04758897: Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 18 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Advanced Malignant Solid Tumor | 03/22 | 12/22 | | |
NCT04806464: Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer |
|
|
| Recruiting | 1 | 44 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161 | CNBG-Virogin Biotech (Shanghai) Ltd. | Primary Liver Cancer | 03/22 | 12/24 | | |
ACTRN12620000244909: A first-in-human study of VG161 in participants with advanced malignant tumours that have not responded to conventional therapies. |
|
|
| Terminated | 1 | 36 | | | Virogin Biotech Australia Pty. Ltd., Virogin Biotech Australia Pty. Ltd. | Advanced malignant solid tumors | | | | |
